File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment outcome and prognostic factors for primary nasal lymphoma

TitleTreatment outcome and prognostic factors for primary nasal lymphoma
Authors
Issue Date1995
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal Of Clinical Oncology, 1995, v. 13 n. 3, p. 666-670 How to Cite?
AbstractPurpose: To report our experience managing a large series of Chinese patients with primary nasal lymphoma. Patients and Methods: From January 1975 to December 1993, 100 patients (median age, 50 years) with newly diagnosed primary nasal lymphoma were studied. There were four low-grade, 62 intermediate-grade, nine high-grade, and 25 unclassifiable lymphomas. Immunophenotyping was performed in 45 patients: eight B cell, 35 T cell, and two uncertain. All cases of angiocentric lymphoma that were typed were T cell. Fifty-two patients had stage I disease, 15 had stage II, four had stage III, and 29 had stage IV. Only 15 patients had B symptoms (weight loss, night sweats, and/or fever), and 11 had bulky disease. Thirty-nine patients with clinically localized stage I and II disease received local radiotherapy alone (before 1980), and the remaining 28 stage I and II patients received combination chemotherapy followed by local radiotherapy. The 33 patients with advanced stage III and IV disease were given combination chemotherapy, and additional radiotherapy was given to five of them who had bulky local disease. Results: Significantly higher complete remission rates were observed in patients with early stages of disease and those without B symptoms. Superior disease-free survival after complete remission was observed in patients with stage 1/11 disease. Univariate factors associated with a better overall survival included age less than 60 years, stage I disease, and absence of B symptoms. Survival was significantly better in the subgroup of patients with stage I disease. Conclusion: Patients with nasal lymphoma, especially those with advanced disease, seemed to have a poor prognosis, and their clinical outcome was not improved significantly by the use of chemotherapy instead of radiotherapy or the use of doxorubicin-containing chemotherapeutic regimens.
Persistent Identifierhttp://hdl.handle.net/10722/76403
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorTodd, Den_HK
dc.contributor.authorChan, TKen_HK
dc.contributor.authorChiu, Een_HK
dc.contributor.authorLie, Aen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorChoy, Den_HK
dc.contributor.authorHo, FCSen_HK
dc.date.accessioned2010-09-06T07:20:51Z-
dc.date.available2010-09-06T07:20:51Z-
dc.date.issued1995en_HK
dc.identifier.citationJournal Of Clinical Oncology, 1995, v. 13 n. 3, p. 666-670en_HK
dc.identifier.issn0732-183Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/76403-
dc.description.abstractPurpose: To report our experience managing a large series of Chinese patients with primary nasal lymphoma. Patients and Methods: From January 1975 to December 1993, 100 patients (median age, 50 years) with newly diagnosed primary nasal lymphoma were studied. There were four low-grade, 62 intermediate-grade, nine high-grade, and 25 unclassifiable lymphomas. Immunophenotyping was performed in 45 patients: eight B cell, 35 T cell, and two uncertain. All cases of angiocentric lymphoma that were typed were T cell. Fifty-two patients had stage I disease, 15 had stage II, four had stage III, and 29 had stage IV. Only 15 patients had B symptoms (weight loss, night sweats, and/or fever), and 11 had bulky disease. Thirty-nine patients with clinically localized stage I and II disease received local radiotherapy alone (before 1980), and the remaining 28 stage I and II patients received combination chemotherapy followed by local radiotherapy. The 33 patients with advanced stage III and IV disease were given combination chemotherapy, and additional radiotherapy was given to five of them who had bulky local disease. Results: Significantly higher complete remission rates were observed in patients with early stages of disease and those without B symptoms. Superior disease-free survival after complete remission was observed in patients with stage 1/11 disease. Univariate factors associated with a better overall survival included age less than 60 years, stage I disease, and absence of B symptoms. Survival was significantly better in the subgroup of patients with stage I disease. Conclusion: Patients with nasal lymphoma, especially those with advanced disease, seemed to have a poor prognosis, and their clinical outcome was not improved significantly by the use of chemotherapy instead of radiotherapy or the use of doxorubicin-containing chemotherapeutic regimens.en_HK
dc.languageengen_HK
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_HK
dc.relation.ispartofJournal of Clinical Oncologyen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAge Factorsen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - therapeutic useen_HK
dc.subject.meshCombined Modality Therapyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLymphoma, Non-Hodgkin - mortality - pathology - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMultivariate Analysisen_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshNose Neoplasms - mortality - pathology - therapyen_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshRegression Analysisen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshSurvival Rateen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleTreatment outcome and prognostic factors for primary nasal lymphomaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0732-183X&volume=13&spage=666&epage=677&date=1995&atitle=Treatment+outcome+and+prognostic+factors+for+primary+nasal+lymphomaen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid7884427-
dc.identifier.scopuseid_2-s2.0-0028900432en_HK
dc.identifier.hkuros4464en_HK
dc.identifier.volume13en_HK
dc.identifier.issue3en_HK
dc.identifier.spage666en_HK
dc.identifier.epage670en_HK
dc.identifier.isiWOS:A1995QL03400018-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridTodd, D=7201388182en_HK
dc.identifier.scopusauthoridChan, TK=7402687762en_HK
dc.identifier.scopusauthoridChiu, E=24827833600en_HK
dc.identifier.scopusauthoridLie, A=24284842400en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridChoy, D=8663654500en_HK
dc.identifier.scopusauthoridHo, FCS=7103408147en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats